Histiocytic sarcoma: a population-based analysis of incidence, demographic disparities, and long-term outcomes

Abstract

compared with treatment with placebo. 5 These results show that ruxolitinib reduces splenomegaly in patients with thalassemia and suggest that targeting EPO-EPOR-JAK2-STAT5 axis may limit the excessive proliferation of erythroid progenitors in spleen.